These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30785995)

  • 1. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study.
    Wen R; Zhao M; Chen C; Yang Y; Zhang B
    Endocrine; 2024 Jun; 84(3):989-998. PubMed ID: 38085420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
    Pitoia F; Abelleira E; Cross G
    Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating thyroglobulin to TSH ratio predict long-term efficacy of
    Yin X; Lu C; Sun D; Ji Y; Wang Y; Zheng H; Ma Z; Jia Q; Tan J; Zheng W
    Endocrine; 2024 Jun; 84(3):1064-1071. PubMed ID: 38172344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.
    Parvathareddy SK; Siraj AK; Ahmed SO; Annaiyappanaidu P; Al-Rasheed M; Al-Haqawi W; Qadri Z; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Endocrine; 2024 Oct; 86(1):268-275. PubMed ID: 38696058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
    Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
    Yim JH; Kim EY; Bae Kim W; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Yoon JH; Shong YK
    Thyroid; 2013 Jan; 23(1):58-63. PubMed ID: 22973946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer.
    Ha J; Kim MH; Jo K; Lim Y; Bae JS; Lee S; Kang MI; Cha BY; Lim DJ
    Medicine (Baltimore); 2017 Jul; 96(29):e7512. PubMed ID: 28723762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
    Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
    Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment.
    Han JM; Kim WB; Yim JH; Kim WG; Kim TY; Ryu JS; Gong G; Sung TY; Yoon JH; Hong SJ; Kim EY; Shong YK
    Thyroid; 2012 Aug; 22(8):784-90. PubMed ID: 22780573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.